Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Inclusion Criteria

• •18 to 70 years old (female)
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •Pathologically diagnosed with her-2 negative, ER/PR negative, ER/PR positive after the failure of endocrine treatment, and had not more than three chemotherapy regimens (must include anthracycline-based and yew class), and the final failure of chemotherapy regimens in patients with advanced breast cancer; Note: treatment failure include (1) during or after the completion of six months or less disease progress of neoadjuvant or adjuvant therapy; (2) rescue treatment in progress within 3 months or less
• •Patients with at least one measurable lesions of the advanced breast cancer， measurable lesions has not received radiotherapy or other treatment, unless progress after treatment (measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1 and WHO);
• •Major organ function has to meet the following certeria:
• •1. For results of blood routine test (without blood transfusion within 14 days)
• •1. HB≥100g/L;
• •2. ANC≥1.5×109/L;
• •3. PLT≥75×109/L;
• •2. For results of blood biochemical test：
• •1. TBIL\<1.5ULN；
• •2. ALTand AST\<2.5ULN, but5\<ULN if the transferanse elevation is due to liver metastases；
• •3. Serum creatinine ≤1.25ULN , or calculated creatinine clearance\>45 ml/min(per the Cockcroft-Gault formula); 6.Participants were willing to join in this study, and written informed consent.